Skip to Main content Skip to Navigation
Journal articles

Inhibiting Endothelin Receptors withMacitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma

Abstract : Current treatments for osteosarcoma, combining conventional polychemotherapy and surgery, make it possible to attain a five-year survival rate of 70% in affected individuals. The presence of chemoresistance and metastases significantly shorten the patient’s lifespan, making identification of new therapeutic tools essential. Inhibiting bone resorption has been shown to be an efficient adjuvant strategy impacting the metastatic dissemination of osteosarcoma, tumor growth, and associated bone destruction. Unfortunately, over-apposition of mineralized matrix by normal and tumoral osteoblasts was associated with this inhibition. Endothelin signaling is implicated in the functional differentiation of osteoblasts, raising the question of the potential value of inhibiting it alone, or in combination with bone resorption repression. Using mouse models of osteosarcoma, the impact of macitentan, an endothelin receptor inhibitor, was evaluated regarding tumor growth, metastatic dissemination, matrix over-apposition secondary to RANKL blockade, and safety when combined with chemotherapy. The results showed that macitentan has no impact on tumor growth or sensitivity to ifosfamide, but significantly reduces tumoral osteoid tissue formation and the metastatic capacity of the osteosarcoma. To conclude, macitentan appears to be a promising therapeutic adjuvant for osteosarcoma alone or associated with bone resorption inhibitors.
Complete list of metadata

https://www.hal.inserm.fr/inserm-03625367
Contributor : Dominique Heymann Connect in order to contact the contributor
Submitted on : Wednesday, March 30, 2022 - 6:40:54 PM
Last modification on : Friday, August 5, 2022 - 10:29:57 AM

File

cancers-14-01765-v2.pdf
Publisher files allowed on an open archive

Identifiers

Citation

Javier Muñoz-Garcia, Jorge William Vargas-Franco, Benedicte Brounais-Le Royer, Denis Cochonneau, Jérôme Amiaud, et al.. Inhibiting Endothelin Receptors withMacitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma. Cancers, MDPI, 2022, 14 (7), pp.1765. ⟨10.3390/cancers14071765⟩. ⟨inserm-03625367⟩

Share

Metrics

Record views

24

Files downloads

7